EZR has been shown to promote tumour progression by modulating the nuclear translocation of YAP in pancreatic cancer and by overexpression in glioblastoma by inactivating the NF2 tumour suppressor, which leads to tumour growth49,50. This evidence concerns the gene NF2 and pancreatic neoplasm.